ATYR PHARMA INC reports an Amendment No. 14 to a Schedule 13G/A disclosing that FMR LLC beneficially owns 5,935,900 shares of Common Stock, representing 6.1% of the class. The filing lists voting and dispositive powers attributed to FMR LLC and Abigail P. Johnson and references an exhibit concerning a 13d-1(k) agreement.
Positive
None.
Negative
None.
Insights
FMR LLC holds a >5% stake in ATYR, reported via a 13G/A amendment.
FMR LLC is disclosed as beneficial owner of 5,935,900 shares (6.1%). The cover-page rows show sole voting and dispositive power amounts attributed to FMR LLC and dispositive power attributed to Abigail P. Johnson.
Timing: the amendment is numbered and signed in early June 2026; subsequent filings may further clarify any changes in holdings or voting arrangements.
The filing is an ownership disclosure amendment with referenced exhibits and powers of attorney.
The schedule references Exhibit 99 for a 13d-1(k) agreement and incorporates powers of attorney by reference. The signatures show authorized filers acting for FMR LLC and Abigail P. Johnson.
Caveat: the excerpt references other exhibits for subsidiary identification and agreement details which are needed to fully interpret control mechanics.
Key Figures
Beneficial ownership:5,935,900 sharesPercent of class:6.1%Sole voting power:5,932,912 shares+1 more
4 metrics
Beneficial ownership5,935,900 sharesAmount beneficially owned as reported on the amended Schedule 13G/A
Percent of class6.1%Percent of common stock represented by the reported shares
Sole voting power5,932,912 sharesSole voting power amount shown on the cover-page rows
Sole dispositive power5,935,900 sharesSole power to dispose as shown in the cover-page rows
Key Terms
Schedule 13G/A, beneficially owned, 13d-1(k) agreement, power of attorney
4 terms
Schedule 13G/Aregulatory
"Amendment No. 14 to a Schedule 13G/A disclosing beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedfinancial
"Amount beneficially owned: 5935900.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
13d-1(k) agreementregulatory
"Please see Exhibit 99 for 13d-1(k) (1) agreement"
power of attorneylegal
"Duly authorized under Power of Attorney effective as of January 3, 2023"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 14)
ATYR PHARMA INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
002120202
(CUSIP Number)
05/29/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
002120202
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,932,912.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,935,900.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,935,900.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
002120202
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,935,900.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,935,900.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ATYR PHARMA INC
(b)
Address of issuer's principal executive offices:
10240 SORRENTO VALLEY ROAD,SUITE 300,SAN DIEGO,CA,USA,92121
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
002120202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
5935900.00
(b)
Percent of class:
6.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
5935900.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ATYR PHARMA INC. No one other person's interest in the COMMON STOCK of ATYR PHARMA INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
06/04/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
06/04/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.
** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
FMR LLC reports beneficial ownership of 5,935,900 shares, representing 6.1% of ATYR common stock. The filing attributes sole voting and dispositive powers to FMR LLC and lists dispositive power for Abigail P. Johnson.
Who signed the Schedule 13G/A amendment for ATYR?
The amendment is signed by Stephanie J. Brown, as duly authorized under powers of attorney on behalf of FMR LLC and Abigail P. Johnson, with signature dates shown as 06/04/2026.
Does the filing name other parties with >5% ownership of ATYR?
The filing states that one or more other persons may have rights to dividends or proceeds, but it also discloses that no other single person's interest exceeds 5% of total outstanding common stock.
What additional documents does the 13G/A amendment reference?
The amendment references Exhibit 99 for a 13d-1(k) agreement and incorporates powers of attorney by reference to previously filed exhibits; those exhibits contain subsidiary identification and authority details.
